| Methods |
RCT
Study aim clearly defined: yes
Blinded assessor of primary outcome: not stated
Double blind study: not stated
Participants comparable at baseline for age: not stated Sex: not stated Duration of complaint: not stated
Inclusion and exclusion criteria specified: yes
Interventions well described: yes
Assessment of compliance: not stated
Intention to treat analysis: not stated
A Priori sample size calculation: not stated
Fungi identified:yes
Distribution of species between groups: yes
Adverse events reported: yes
Number of drop outs stated: yes |
| Participants |
Total evaluable sample size: 43
Exclusion criteria: Bacterial/ yeast infection, use of topical antifungal therapy within two weeks prior to study, use of systemic griseofulvin or ketoconazole within four weeks prior to study
Treatment setting: Dermatological departments |
| Interventions |
a. Terbinafine 1% cream
Duration: four weeks
Frequency: applied once daily
b. Bifonazole 1% cream
Duration: four weeks
Frequency: applied once daily |
| Outcomes |
Primary outcome: cure
Secondary Outcomes: Signs and symptoms
‐ itching, erythema, scaling
Adverse events: none in either group |
| Notes |
|
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment (selection bias) |
Low risk |
A ‐ Adequate |
